Low molecular weight heparins

Journal of Internal Medicine

Volumn 240, Issue 2, 1996, Pages 63-72

  Bergqvist, David ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Deep Vein thrombosis; Haemodialysis; Low molecular weight heparin; Postoperative complications; Pulmonary embolism

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PLACEBO; REVIPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MANUFACTURE; HEMODIALYSIS; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PHARMACODYNAMICS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0029849753     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.494834000.x     Document Type: Review

References (99)

1. Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: Separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976; 66: 90-3.
2. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sonderström G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575.
3. Lam LH, Silberg JA, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-7.
4. Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
5. Esquivel CO, Bergqvist D, Björck C-G, Nilsson B. Effect of heparin and a heparinoid on platelet activity and microvascular haemostasis in vivo. Eur Surg Res 1982; 14: 154.
6. Hoppensteadt DA, Haas S, Breddin HK, Fareed J. Modulation of laboratory parameters after therapeutic and prophylactic administration of sandoparin. Semin Thromb Hemost 1993; 19: S31-5.
7. Østergaard PB, Nilsson B, Bergqvist D, Hedner U, Pedersen PC. The effect of low molecular weight heparin on experimental thrombosis and haemostasis - the influence of production method. Thromb Res 1987; 45: 739-49.
8. Lindahl U, Backström G, Höök M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site of heparin. Proc Natl Acad Sci USA 1979; 76: 3198-202.
9. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979; 76: 1218-22.
10. Choay J, Pettou M, Lormeau J, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-9.
11. Rosenberg RD, Jordan RE, Favreau LV, Lam LH. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979; 86: 1319-24.
12. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300-4.
13. Dryjski M, Mikat E, Bjornsson T. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid. J Vasc Surg 1988; 8: 623-33.
14. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamens J, Schmid KM et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation 1992; 85: 1548-56.
15. Wilson NV, Salisbury JR, Kakkar VV. Effect of low molecular weight heparin on intimal hyperplasia. Br J Surg 1991; 78: 1381-3.
16. Bergqvist D, Siegbahn A. Effects of heparin on the vessel wall and blood cellular elements. Vasc Med Rev 1993; 4: 221-33.
17. 1-161) in an experimental venous thrombosis model. Haemostasis 1993; 23 (Suppl.): 112-7.
18. Brunkwall J, Mätzsch T, Bergqvist D. The effect of unfractionated and low-molecular-weight heparin on the release of prostacyclin from the arterial wall. Blood Coagul Fibrinolysis 1990; 1: 641-5.
19. Horne MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74: 306-12.
20. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
21. Bengtsson G, Olivecrona T, Höök M, Riesenfeld J, Lindahl U. Interaction of lipoprotein lipase with native and modified heparin-like polysaccharides. Biochem J 1980; 189: 625-33.
22. Persson E, Nordenström J, Nilson-Ehle P, Hagenfeldt L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur J Clin Inv 1985; 15: 215-20.
23. Olivecrona T, Bengtsson-Olivecrona G, Østergaard P, Liu G, Chevreuil O, Hultin M. New aspects on heparin and lipoprotein metabolism. Haemost 1993; 23: S150-60.
24. Bergqvist D, Hedner U, Sjörin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administrated subcutaneously. Thromb Res 1983; 32: 381-91.
25. Mätzsch T, Bergqvist D, Hedner U, Østergaard PB. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 97-101.
26. Boneau B, Dol F, Caranobe C, Sie P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-91.
27. Bendetowicz V, Béguin S, Caplain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (Enoxaparin) after subcutaneous injection, comparison with unfractionated heparin - A three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13.
28. Albada J, Nieuwenhuis HK, Sixma JJ. Pharmacokinetics of standard and low molecular weight heparin. In: Lane DA, Lindahl U, eds. Heparin. London, Melbourne, Auckland: Edward Arnold, Division of Hodder and Stoughton, 1989.
29. Palm M, Mattson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin®) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-5.
30. Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 1985; 38: 11-20.
31. Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U et al. Protamine neutralization of intravenous and subcutaneous LMWH (tinzaparin, Logiparin). An experiment investigation in healthy volunteers. Blood Coagula Fibrinolysis 1995; 5: 795-803.
32. Padilla A, Gray E, Pepper DS, Barrowcliffe TV. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Brit J Haematol 1992; 82: 406-13.
33. Diness V, Østergaard P. Neutralization of a low-molecular-weight heparin (LHN-1) and conventional heparin by protamine sulphate in rats. Thromb Haemost 1986; 56: 318-22.
34. Bergqvist D. Review of clinical trials of low molecular weight heparins. Eur J Surg 1992; 158: 67-78.
35. Nurmohammed MT, Rosendaal FR, Büller HR, Dekker E, Hommes D, Vandenbroucke J et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-6.
36. Leizorovicz A, Haugh MC, Chapuis F-R, Samama MM, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
37. Kakkar VV. Efficacy and safety of clivarin® and other LMWHs in general surgery: a meta-analysis. Blood Coagul Fibrinolysis 1993; 4: S23-7.
38. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12.
39. Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704.
40. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-5.
41. Mätzsch T, Bergqvist D, Fredin H, Hedner U. Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement. Acta Chir Scand 1990; 156: 445-50.
42. The Danish Enoxaparin Study Group. Low molecular weight heparin (enoxaparin) vs dextran-70. The prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991; 151: 1621-4.
43. Reiertsen D, Larsen S, Størkson R, Trondsen E, Løvig T, Andersen OK et al. Safety of enoxaparin and dextran-70 in the prevention of venous thromboembolism in digestive surgery. A play-the-winner-designed study. Scand J Gastroenterol 1993; 28: 1015-20.
44. Pezzuoli G, Serneri GGN, Settembrini P, Coggi G, Olivari N, Buzzetti G et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). Int. Surg 1989; 74: 205-10.
45. Collins R, Scrimgeour A, Yusuf S, Phil D, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopaedic, and urologic surgery. N Engl J Med 1988; 318: 1162-73.
46. Eriksson BI, Kälebo P, Anthmyr BA, Wadenvik H, Tengborn L, Risberg B. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg 1991; 73A: 484-93.
47. Planes A, Vochelle N, Mazas F, Manzat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-10.
48. Leyvraz PF, Bachmann F, Hoek J, Büller HR, Postel M, Samama M et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ 1991; 303: 543-8.
49. The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. Arch Orthop Trauma Surg 1992; 111: 110-20.
50. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Brit J Surg 1995; 82: 496-501.
51. Nicolaides AN, Bergqvist D, Comerota AJ, Cooke ED, Scurr JH. European Consensus Statement. Prevention of venous thromboembolism. Int Angiol 1992; 11: 151-9.
52. Bergqvist D, Mätzsch T, Burmark US, Frisell J, Guilbaud O, Hallböök T et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in the prevention of thrombosis after elective general abdominal surgery. Br J Surg 1988; 75: 888-91.
53. Mätzsch T, Bergqvist D, Burmark US, Holmer E, Söderberg K. The influence of surgical trauma on factor XaI- IIaI-activity and heparin concentration after a single dose of low molecular weight heparin. Blood Coagul Fibrinolysis 1991; 2: 651-7.
54. Colwell CW, Spiro TE, Trowbridge AA, Morris BA, Kwaan HC, Blaha JD et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994; 76A: 3-14.
55. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blasier RB et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994; 121: 81-9.
56. Hull RD, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-6.
57. Tryba M und die Teilnehmer des Workshop über hämostaseologische Probleme bei Regionalanaesthesien. Haemostaseologische Voraussetzungen zur Durch-führung von Regionalanaesthesien. Regional-Anaesthesie 1989; 12: 127-31.
58. Bergqvist D, Lindblad B, Mätzsch T. Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia - is there a risk? Acta Anaesthesiol Scand 1992; 36: 605-9.
59. Wolf H. Experience with regional anaesthesia in patients receiving low molecular weight heparins. Semin Thromb Hemost 1993; 19: S152-9.
60. 125I-labelled fibrinogen uptake test. Br J Surg 1984; 71: 511-5.
61. Prins MH, Gelsema R, Sing AK. Prophylaxis of deep venous thrombin with a low molecular weight heparin (Kabi 2165/ Fragmin) in stroke patients. Haemost 1989; 19: 245-50.
62. Green D, Lee MY, Lim AC, Chmiel J, Vetter M, Pang T et al. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Ann Intern Med 1990; 113: 571-1.
63. Dahan R, Houlbert D, Caulin C, Cuzin E, Vitart C, Woler M et al. Prevention of deep vein thrombosis in elderly medical inpatients by a low-molecular weight heparin: a randomized double-blind trial. Haemost 1986; 16: 159-64.
64. Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. Semin Thromb Hemost 1993; 19: S131-41.
65. Bratt G, Törnebohm E, Granqvist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-7.
66. Albada J, Niuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation 1989; 80: 935-40.
67. Bratt G, Åberg W, Johansson M, Törnebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10.
68. Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251-6.
69. Prandoni P, Lensing A, Büller HR, Carta M, Cogo A, Vigo M et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5.
70. Lopacuik S, Meissner J, Filipecki S, Zaeilska K, Sowier J, Ciesielski L et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14-8.
71. Hull DH, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliot CG et al. Subcutaneous low-mole-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
72. Lindmarker P, Holmström M, Granqvist S, Johnson H, Lockner D. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72: 186-90.
73. Leizorovicz A, Simonneau G, Decousus H, Boisse JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 229-304.
74. Marder VJ, Soulen RL, Atichartakarn VM, Budzynski AZ, Parulekar S, Edward KN et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-29.
75. Arnesen H, Heilo A, Jakobsen E, Ly B, Skaga E. A prospective study on streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978; 203: 457-63.
76. Bergqvist D, Lindgren B, Mätzsch T. Cost-effectiveness of preventing postoperative deep vein thrombosis. In: Hull R, Raskob G, eds. Venous thromboembolism. Philadelphia: WB Saunders, 1995: 228-33.
77. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742-6.
78. Menzin J, Richner R, Huse D, Colditz, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994; 28: 271-5.
79. Borris LC, Lassen MR, Jensen HP, Andersen BS, Poulsen KS. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Intern J Clin Pharmacol Therap 1994; 32: 262-8.
80. Andrew M, Boneu B, Cade J, Cerskus AL, Hirsh J, Jefferies A et al. Placental transport of low molecular weight heparin in the pregnant sheep. Br J Hematol 1985; 59: 103-8.
81. Mätzsch T, Bergqvist D, Bergqvist A, Hodson S, Dawes J, Hedner U et al. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin. Blood Coagul Fibrinolysis 1991; 2: 272-8.
82. Mätzsch T, Bergqvist D, Hedner U, Nilsson B, Østergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990; 63: 505-9.
83. Wahlberg TB; Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. Haemostasis 1994; 24: 55-6.
84. Nurmohammed MT, Büller HR, ten Cate JW. Low molecular weight heparins in extracorporeal circuits. In: Bounameaux H, ed. Low Molecular Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. New York: Marcel Dekker Inc. 1994: 247-71.
85. Matthiasson S, Bergqvist D, Lundell A, Lindbald B. Effect of dextran and enoxaparin on early ePTPE graft thrombogenicity in sheep. Eur J Vasc Endovasc Surg 1995; 9: 284-92.
86. Farkas JC, Chapuis C, Combe S, Siesiguen M, Marzelle J, Laurian C, Cormier JM. A randomised controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. Eur J Vasc Surg 1993; 7: 554-60.
87. Currier JW, Pow TK, Haudenschild CC, Minihan AC, Faxon DP. Low molecular weight heparin (Enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 118B-25B.
88. Buchwald AB, Unterberg C, Nebendahl K, Gröne H-J, Wiegand V. Low molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation 1992; 86: 531-7.
89. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 334: 914-8.
90. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial Circulation 1994; 90: 908-14.
91. Bergqvist D, Burmark US, Frisell J, Hallböök T, Lindblad B, Risberg B et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-8.
92. Koller M, Schoch U, Buchmann P, Largiadér F, von Felten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost 1986; 56: 243-6.
93. Schimdt-Hübner U, Bünte H, Freise G, Reers B, Rüschemeyer C, Sherer R et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-53.
94. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK et al. Low molecular weight heparin versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
95. Wolf H. Low-molecular-weight heparin. Med Clin North Am 1994; 78: 733-43.
96. Ojeda E, Perez MC, Mataiz R, Arbelo A, Jimenez S, Campo C et al. Skin necrosis with a low molecular weight heparin. Br J Haematol 1992; 82: 620.
97. Lecompte T, Luo SK, Stieltjes N, Lecrubier C, Samama MM. Thrombocytopenia associated with low-molecular-weight heparin. Lancet 1991; 338: 1217.
98. Warkentin T, Levine M, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin indured thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
99. Leroy J, Ledere MH, Delahousse B, Guierois C, Foloppe P, Gruel Y et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY216) Semin Thromb Hemost 1985; 11: 326-9.